Pacira BioSciences Inc. Secures $300 Million Credit Agreement with Wells Fargo and Lenders, Refinances Existing Debt

Reuters
2025/07/07
Pacira BioSciences Inc. Secures $300 Million Credit Agreement with <a href="https://laohu8.com/S/EOD">Wells Fargo</a> and Lenders, Refinances Existing Debt

Pacira BioSciences Inc. has entered into a new Credit Agreement with Wells Fargo Bank, National Association, and other lenders as of July 3, 2025. This agreement involves a senior secured revolving credit facility with a commitment amount of $300 million, aimed at refinancing Pacira's previous term loan A facility and providing ongoing working capital. The facility, which matures on July 3, 2030, includes a $10 million letter of credit sublimit and a $15 million swingline loan sublimit, secured by the assets of the company and its subsidiaries. The new arrangement allows for potential expansion through incremental term facilities. Notably, Pacira terminated its existing credit agreement without incurring prepayment penalties.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-065979), on July 07, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10